The combination of cytotoxic chemotherapy and EGFR-TKIs has emerged as a potential first-line treatment option after SCLC transformation, demonstrating improved Progression-Free Survival (PFS) compared to mono-chemotherapy. This evidence concerns the gene EGFR and small cell lung carcinoma.